| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5697258 | Bulletin du Cancer | 2017 | 7 Pages |
Abstract
Pomalidomide is a second-generation immunomodulatory drug (IMID). Its efficiency overtakes its predecessors' (thalidomide, lenalidomide), with less toxicity. It is indicated in the treatment of refractory or relapsed multiple myeloma, associated to dexamethasone. It is available in France since 2013, following the results of different studies.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Aurore Dougé, Richard Lemal, Carine Chaleteix,